GlassScriptPhysician profile
Kevin Darly Eric Williams
NPI 1871870832
$1,259.73
in general payments reported to CMS, 2019-2025
12 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $496 · 2023: $268 · 2024: $113 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $347.51 | 2022-2024 | Camzyos |
| Amgen INC. | $249.68 | 2021-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $213.59 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $152.72 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $67.14 | 2022-2023 | Lokelma |
| Gilead Sciences, INC. | $52.89 | 2025 | Biktarvy |
| Chiesi USA, INC. | $43.40 | 2022 | |
| Cardiva Medical, INC. | $39.40 | 2025 | Cardiva Vascade 5f Vcs |
| Shockwave Medical, INC | $28.05 | 2021 | |
| Esperion Therapeutics, INC. | $24.03 | 2025 | Nexletol |
| Astellas Pharma US INC | $20.71 | 2023 | |
| Novo Nordisk INC | $20.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.